CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 62 filers reported holding CRISPR THERAPEUTICS AG in Q3 2017. The put-call ratio across all filers is 1.87 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $217,000 | -32.6% | 2,870 | -0.1% | 0.02% | -36.1% |
| Q3 2021 | $322,000 | -30.8% | 2,873 | 0.0% | 0.04% | -30.8% |
| Q2 2021 | $465,000 | +32.9% | 2,873 | 0.0% | 0.05% | +30.0% |
| Q1 2021 | $350,000 | -20.5% | 2,873 | 0.0% | 0.04% | -25.9% |
| Q4 2020 | $440,000 | +83.3% | 2,873 | 0.0% | 0.05% | +54.3% |
| Q3 2020 | $240,000 | +133.0% | 2,873 | 0.0% | 0.04% | +105.9% |
| Q1 2019 | $103,000 | +151.2% | 2,873 | +101.6% | 0.02% | +142.9% |
| Q4 2018 | $41,000 | -34.9% | 1,425 | 0.0% | 0.01% | -30.0% |
| Q3 2018 | $63,000 | -25.0% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q2 2018 | $84,000 | +29.2% | 1,425 | 0.0% | 0.01% | +27.3% |
| Q1 2018 | $65,000 | +97.0% | 1,425 | 0.0% | 0.01% | +120.0% |
| Q4 2017 | $33,000 | +32.0% | 1,425 | 0.0% | 0.01% | +25.0% |
| Q3 2017 | $25,000 | +8.7% | 1,425 | 0.0% | 0.00% | -20.0% |
| Q2 2017 | $23,000 | -25.8% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $31,000 | – | 1,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |